3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab FlopThe Motley Fool • 03/30/19
The Hits Just Keep Coming For Biogen As Rival Gains MS Drug ApprovalInvestors Business Daily • 03/27/19
Biogen sets new $5 billion stock repurchase program in aftermath of stock plungeMarket Watch • 03/25/19
Failed Alzheimer's trial leaves families and patients heartbroken. Medical community reelsCNBC • 03/23/19
Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'Benzinga • 03/22/19
Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinuedMarket Watch • 03/21/19